2019
DOI: 10.18502/ijaai.v18i5.1919
|View full text |Cite
|
Sign up to set email alerts
|

Immunological Responses against HER2-Targeted Idarubicin-ZHER2 Conjugate in BALB/c Mice

Abstract: Targeting of cancerous cells with a high level of human epidermal growth factor receptor 2 (HER2) expressions by drug immunoconjugates is a new approach for specific delivery of chemotherapeutic agents. Our previous work indicated that idarubicin-ZHER2 affibody conjugate has a great potential for the treatment of HER2-overexpressing malignant cell lines but possible induced immune response against constructed conjugate was not addressed. In the current study, the possibility of induction of humoral and c… Show more

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles